The IncRNA GATA3-AS1/miR-495-3p/CENPU axis predicts poor prognosis of breast cancer via the PLK1 signaling pathway

Shuangyan Lin¹, Mingyuan Zhao¹, Yanbo Lv¹, Genxiang Mao², Shiping Ding³, Fang Peng¹,*

¹Department of Pathology, Zhejiang Hospital, Hangzhou, Zhejiang, China
²Department of Geriatrics, Zhejiang Provincial Key Lab of Geriatrics, Hangzhou, Zhejiang, China
³Department of Cell Biology, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Correspondence to: Shiping Ding, Fang Peng; email: dingshiping@zju.edu.cn; pengfang999@139.com, https://orcid.org/0000-0002-7037-2307

Keywords: breast cancer, CENPU, bioinformatics analysis, miRNA, IncRNA

Received: August 5, 2020  Accepted: March 22, 2021  Published: April 26, 2021

Copyright: © 2021 Lin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

The function of centromere protein U (CENPU) gene in breast cancer has not been well understood. Therefore, we explored the expression profiles of CENPU gene in breast carcinoma to better understand the functions of this gene, as well as the relationship between CENPU expression and the prognosis of breast carcinoma patients. Our results indicate that CENPU was expressed at significantly higher levels in cancerous tissues than in normal tissues. Furthermore, CENPU expression correlated significantly with many clinicopathological characteristics of breast cancer. In addition, we discovered that high levels of CENPU expression predicted poor prognosis in patients with breast cancer. Functional investigation revealed that 180 genes exhibited co-expression with CENPU. Functional annotation indicated that 17 of these genes were involved in the PLK1 signaling pathway, with most of them (16/17) being expressed at significantly higher levels in malignant tissues compared with normal controls and correlating with a poor prognosis. Subsequently, we found that four miRNAs, namely hsa-miR-543, hsa-miR-495-3p, hsa-miR-485-3p, and hsa-miR-337-3p, could be regarded as potential CENPU expression regulators. Then, five IncRNAs were predicted to potentially bind to the four miRNAs. Combination of the results from expression, survival, correlation analysis and functional experiments analysis demonstrated the link between IncRNA GATA3-AS1/miR-495-3p/CENPU axis and prognosis of breast cancer. In conclusion, CENPU could be involved in cell cycle progression through PLK1 signaling pathway.

INTRODUCTION

Breast cancer is common malignancy threatening female health globally. It is predicted that the incidence and mortality rate of breast cancer will rise substantially within the next 5 to 10 years [1]. As a type of aggressive malignancy with high heterogeneity, breast carcinoma has been connected with complex biological events. The occurrence of breast cancer even at a young age highlights its heterogeneity and complexity [2, 3]. Although chemotherapy, surgical resection, and radiotherapy have improved outcomes for breast cancer patients over the recent decades, the median survival of breast cancer patients with metastasis remains disappointedly low (around 24 months) [4]. Mechanisms underlying the development and progression of breast cancer remain unclear. Therefore, it is necessary to investigate the underlying molecular events and identify novel therapeutic targets and prognostic biomarkers for effective management of breast cancer.

Centromere protein U (CENPU) gene is localized at 4q35.1 in human genome. The gene spans a genomic DNA region of 75.8 kilobases (kb) and consists of 14 exons. The protein product of this gene is the centromere protein that mediates sister chromatid cohesion. CENPU is involved in the regulation of cell cycle progression and is implicated in the control of centromere function and sister chromatid cohesion. Studies have shown that CENPU may play a role in the development and progression of breast cancer. However, the specific functions and mechanisms of CENPU in breast cancer remain unclear.
assembly, mitotic progression, and segregation of chromosomes [6, 7]. Our previous study demonstrated that CENPU downregulation might inhibit the proliferation of human breast cancer cells [8]. However, molecular mechanisms underlying that observation remain undetermined. Therefore, it is important to explore the functions of CENPU and its relationship with survival outcomes and pathohistological characteristics in breast carcinoma patients.

It has been demonstrated that non-coding RNAs, more specifically, microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), play essential roles in tumor progression [9, 10]. Among them, miRNAs are ~22-nucleotide-long non-coding RNAs that regulate target gene expression at the post-transcriptional level [11], while lncRNAs are a class of non-coding transcripts implicated in multiple biological events, such as cell differentiation, cell growth, transcriptional and post-transcriptional regulation of gene expression, and immune activation/ inactivation [12, 13]. In our current study, we also tried to identify miRNAs and lncRNAs that can regulate CENPU expression in breast cancer.

RESULTS

CENPU gene mutations in breast cancer

CENPU gene mutations in breast cancer patients were retrieved from the Catalogue of Somatic Mutations in Cancer (COSMIC) database (https://cancer.sanger.ac.uk/cosmic). Before April 7, 2020, CENPU gene in specimens from 37,419 patients had been sequenced, leading to the identification of 297 unique samples with CENPU mutations (Table 1). Among the identified mutations, 122 were point mutations, including six nonsense substitutions, 94 missense substitutions, and 22 synonymous substitutions, 3 were frameshifting insertions, and one was frameshifting deletion; No inframe deletions, inframe insertions, or complex mutations were identified (Table 1). Taken together, these data indicate a low incidence of CENPU gene mutation in breast carcinoma patients, implying that CENPU gene mutation might not be the reason for the differences in gene expression.

Aberrant CENPU expression in breast carcinoma

An aberrant high expression of a gene in cancerous tissues is a significant indicator that the gene can be considered as a diagnostic or prognostic biomarker [14]. In view of this, based on the HPA database, we determined CENPU mRNA expression levels in normal and cancerous tissues. CENPU expression was observed in both normal and malignant breast tissues (Figure 1A–1B). Next, we conducted an analysis of CENPU expression in tissue samples deposited in The Cancer Genome Atlas (TCGA) and Clinical Proteomic Tumor Analysis Consortium (CPTAC) databases by using the online database UALCAN. We observed that both the mRNA and protein levels of CENPU were significantly higher in malignant tissues than in normal tissues (Figure 1C–1D). In addition, our previous study found significantly increased CENPU levels in malignant tissues than in adjacent normal breast tissues [8]. Taken together, these findings imply that CENPU may be a potential biomarker for breast carcinoma.

Subsequently, differences in CENPU expression in breast carcinoma patients with different clinical and pathological parameters were determined based on bcGenExMiner. We found significant correlation between CENPU expression and the age of breast cancer patients, with higher CENPU expression levels being observed in patients aged ≤51 years than in patients aged >51 years (Figure 2A). In addition, there were significant correlations between CENPU expression and Scarff-Bloom-Richardson (SBR) grade (Figure 2B) and neuropsychiatric inventory (NPI) score (Figure 2C). Furthermore, CENPU was markedly upregulated in patients with lymph node metastasis (Figure 2D), as well as in estrogen receptor (ER)-negative (Figure 2E), progesterone receptor (PR)-negative (Figure 2F), and human epidermal growth factor receptor 2 (HER2)-positive breast carcinoma patients (Figure 2G). The expression of CENPU also differed considerably among different HU’s (Figure 2H) and robust single sample predictor classification (RSSPC) subtypes (Figure 2I). Finally, we also found a significantly higher CENPU expression in basal-like breast carcinoma (Figure 2J), triple-negative breast carcinoma (TNBC) (Figure 2K), and basal-like & triple-negative breast triple-negative breast carcinoma (Figure 2L), compared with non-basal-like breast cancer, non-TNBC, and non-basal-like & non-triple-negative breast carcinoma, respectively.

According to eight studies included in the Oncomine database, the expression of CENPU was significantly higher in TNBC patients than in non-TNBC patients (fold change > 1.5, gene rank: top 10%) (Table 2). All these data suggest that CENPU is not only an indicator of breast cancer, but also a molecular indicator of triple-negative breast carcinoma.

Correlation of CENPU expression with prognosis of breast carcinoma patients

We next explored the prognostic significance of CENPU expression in breast cancer. Two probes (218883_s_at and 229305_at) related to CENPU were retrieved from the Kaplan-Meier plotter database (Figure 3). We found that CENPU expression...
Table 1. Genetic alterations affecting CENPU in 37419 unique samples from the COSMIC database (297 unique samples with mutations in the COSMIC database).

| Genetic alteration       | Number | Percentage (%) total number 297 | Percentage (%) total number 37419 |
|--------------------------|--------|---------------------------------|----------------------------------|
| Nonsense substitution    | 6      | 2.02                            | 0.0002                           |
| Missense substitution    | 94     | 31.65                           | 0.0025                           |
| Synonymous substitution  | 22     | 7.41                            | 0.0006                           |
| Inframe insertion        | 0      | 0                               | 8.02E-05                         |
| Frameshift insertion     | 3      | 1.01                            | 0                                 |
| Inframe deletion         | 0      | 0                               | 2.67E-05                         |
| Frameshift deletion      | 1      | 0.34                            | 0                                 |
| Complex mutation         | 0      | 0                               | 0                                 |
| Other                    | 30     | 10.10                           | 0.0008                           |

significantly correlated with overall survival (OS), distant metastasis-free survival (DMFS), and relapse-free survival (RFS) in breast carcinoma patients. Specifically, high expression of CENPU was predictive of significantly poorer OS, RFS, and DMFS in both probes analyzed. Then we used the PrognoScan database to assess the correlation between CENPU expression and prognosis of breast carcinoma patients (Table 3). According to our analysis, CENPU expression level correlated significantly with OS, RFS, DMFS, disease-free survival, and disease-specific survival. Similarly, high CENPU expression was correlated with higher hazard ratios in breast carcinoma patients. All these data suggest that CENPU expression is also an indicator of prognosis of breast carcinoma patients.

The involvement of CENPU in the PLK1 signaling pathway

To better understand the functions of CENPU, we utilized three databases (cBioPortal, GEPIA, and

Figure 1. CENPU expression in normal and cancerous tissues. (A) CENPU mRNA expression in different normal tissues from the HPA database. (B) CENPU mRNA expression in different cancer tissues from the HPA database. (C–D) The mRNA and protein level expression of CENPU in breast cancer compared with normal tissue by analyzing UALCAN database, **P < 0.01.
UALCAN) to identify genes that exhibited co-expression with CENPU. We found that the number of genes co-expressed with CENPU was 214, 1001, and 1094, as revealed by the cBioPortal, GEPIA, and UALCAN databases, respectively (Figure 4A). Venn diagram showed that the number of genes exhibited co-expression with CENPU was 180. To gain a better understanding of these genes, we conducted gene ontology (GO) annotation and pathway enrichment analyses with the Enrichr database (Figure 4B–4G). For functional annotation, three categories of GO term were analyzed, including biological process, cellular component, and molecular function. For pathway enrichment, cell signaling pathways included in the NCI-Nature Pathway, Reactome Pathway, and Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway were analyzed. As presented in Figure 4B–4D, the top two GO terms enriched were DNA metabolic process and DNA replication in the GO category of biological process, spindle and mitotic spindle in the category of cellular component, and microtubule binding and tubulin binding in the category of molecular function. As shown in Figure 4E–4G, the most enriched pathways in the three GO categories were cell cycle-related. It is noteworthy that the PLK1 signaling pathway was the most enriched signaling cascade in the NCI-Nature Pathway.

Since the PLK1 signaling pathway is associated with cell cycle, we next focused on PLK1 signaling-related events. In addition to CENPU, there were 17 other genes enriched in the PLK1 signaling cascade (Table 4). The correlation coefficients between these genes and CENPU were in the range of 0.32-0.69 according to the cBioPortal, GEPIA, and UALCAN databases. Next, we compared the expression levels of these 17 genes in breast carcinoma tissues with those in normal controls.

Figure 2. Differences in CENPU expression between breast cancer patients with different clinicopathological features. The clinicopathological features analyzed included (A) age, (B) SBR grade, (C) NPI score, (D) nodal status, (E) ER status, (F) PR status, (G) HER2 status, (H) HU’s subtype, (I) RSPC subtype, (J) basal-like status, (K) triple-negative status, (L) triple-negative and basal-like status.
Table 2. Elevated CENPU expression in TNBC from Oncomine database.

| Study name         | TNBC patient number | NON-TNBC patient number | Fold change | P-value (TNBC&NON-TNBC) |
|--------------------|---------------------|-------------------------|-------------|------------------------|
| Curtis breast      | 211                 | 1340                    | 2.14        | 7.02E-57               |
| TCGA breast        | 46                  | 250                     | 3.04        | 1.84E-20               |
| Bitter breast      | 39                  | 129                     | 2.40        | 4.33E-8                |
| Hatzis breast      | 178                 | 320                     | 1.59        | 8.22E-17               |
| Zhao breast        | 5                   | 29                      | 3.63        | 5.90E-4                |
| Waddell breast     | 22                  | 44                      | 2.15        | 1.01E-5                |
| Kao breast         | 32                  | 295                     | 1.99        | 1.13E-15               |
| Richardson breast 2| 18                  | 19                      | 2.09        | 5.80E-4                |

by utilizing the UALCAN database (Figure 5). All these genes showed a significantly higher expression in malignant tissues than in their normal counterparts. We then determined the prognostic significance of these genes in breast cancer by utilizing the Kaplan-Meier plotter database and found that high expression levels of 16 genes were associated with poor OS (Figure 5). These results were similar to those observed on CENPU. Gene Set Enrichment Analysis (GSEA) showed that the 17 genes co-expressed with CENPU were enriched in PLK1 pathway, G2/M cell cycle, cell cycle mitotic, and cell cycle from reactome in TNBC along with high expression of CENPU (Figure 6A–6D). All these data imply that CENPU may be involved in cell cycle progression through the PLK1 signaling pathway. The details of PLK1 pathway enriched genes in TNBC patients with CENPU high vs. CENPU low was shown in the Supplementary Table 1.

**Figure 3.** Determination of prognostic significance of CENPU expression (Affymetrix IDs are valid: 218883_s_at and 229305_at) in patients with breast cancer from Kaplan-Meier plotter database. (A, D) OS curves established according to CENPU expression. (B, E) RFS curves established according to CENPU expression. (C, F) DMFS curves established according to CENPU expression.
Identification of key miRNAs that can potentially regulate CENPU expression

MicroRNAs are endogenous RNAs that modulate expression of target genes post-transcriptionally [11]. Based on the functions of CENPU in breast cancer, we used the starBase database to predict miRNAs that can potentially regulate CENPU expression and identified eight such miRNAs, namely hsa-miR-543, hsa-miR-495-3p, hsa-miR-493-3p, hsa-miR-656-3p, hsa-miR-1295a, hsa-miR-485-3p, hsa-miR-337-3p, and hsa-miR-411-5p (Table 5). Furthermore, we assessed correlations between the expression levels of these predicted miRNAs and CENPU expression using the OncomiR database. Seven miRNAs, including hsa-miR-543, hsa-miR-495-3p, hsa-miR-493-3p, hsa-miR-656-3p, hsa-miR-1295a, hsa-miR-485-3p, hsa-miR-337-3p, and hsa-miR-411-5p, were found downregulated in malignant tissues compared with normal controls (Table 6). Based on the Kaplan-Meier plotter database, we subsequently evaluated prognostic significance of these miRNAs in breast cancer (Figure 7) and found that higher expression levels of five miRNAs (namely hsa-miR-543, hsa-miR-495-3p, hsa-miR-1295a, hsa-miR-485-3p, and hsa-miR-337-3p) were predictive of a more favorable prognosis. It is well accepted that the expression of a miRNA is negatively associated with that of its target mRNA [15]. Given that larger correlation coefficients indicate stronger correlations, four miRNAs (namely hsa-miR-543, hsa-miR-495-3p, hsa-miR-485-3p, and hsa-miR-337-3p) with correlation coefficient absolute values above 0.1 were regarded as the “key miRNAs”.

Identification of key lncRNAs that can potentially regulate the key miRNAs

Growing evidence has suggested that lncRNAs can function as ceRNAs to interact with miRNA by competing for shared miRNA [16]. Based on this principle, we used the starBase database to identify

Table 3. Relationship between CENPU expression and prognosis in breast cancer patients from PrognoScan database.

| Dataset         | Endpoint                          | Probe ID   | Number | Cox p-value | HR [95% CI]   |
|-----------------|-----------------------------------|------------|--------|-------------|---------------|
| GSE12276        | Relapse Free Survival             | 218883_s_at| 204    | 0.04116360  | 1.26 [1.01–1.57] |
| GSE6532-GPL570  | Distant Metastasis Free Survival  | 229304_s_at| 87     | 0.00262684  | 2.34 [1.34–4.07] |
| GSE6532-GPL570  | Relapse Free Survival             | 229305_at  | 87     | 0.01880120  | 1.59 [1.08–2.34] |
| GSE6532-GPL570  | Distant Metastasis Free Survival  | 229305_at  | 87     | 0.01880120  | 1.59 [1.08–2.34] |
| GSE6532-GPL570  | Relapse Free Survival             | 229304_s_at| 87     | 0.00262684  | 2.34 [1.34–4.07] |
| GSE12093        | Distant Metastasis Free Survival  | 218883_s_at| 136    | 0.01926210  | 2.30 [1.15–4.62] |
| GSE11121        | Distant Metastasis Free Survival  | 218883_s_at| 200    | 0.00213651  | 2.25 [1.34–3.78] |
| GSE2034         | Distant Metastasis Free Survival  | 218883_s_at| 286    | 0.00041530  | 1.86 [1.32–2.62] |
| GSE1456-GPL96   | Overall Survival                  | 218883_s_at| 159    | 0.00015424  | 2.55 [1.57–4.15] |
| GSE1456-GPL96   | Relapse Free Survival             | 218883_s_at| 159    | 0.00006250  | 2.71 [1.66–4.42] |
| GSE3494-GPL96   | Disease Specific Survival         | 218883_s_at| 159    | 0.00034302  | 2.84 [1.60–5.02] |
| GSE3494-GPL97   | Disease Specific Survival         | 218883_s_at| 159    | 0.00217077  | 2.64 [1.42–4.90] |
| GSE1456-GPL97   | Disease Specific Survival         | 229305_at  | 159    | 0.01828760  | 2.11 [1.13–3.92] |
| GSE1456-GPL97   | Disease Specific Survival         | 229305_at  | 159    | 0.02115490  | 2.36 [1.14–4.90] |
| GSE7378         | Disease Free Survival             | 218883_s_at| 54     | 0.02591300  | 2.40 [1.11–5.18] |
| GSE3494-GPL96   | Disease Specific Survival         | 218883_s_at| 236    | 0.00078752  | 2.25 [1.40–3.62] |
| GSE3494-GPL97   | Disease Specific Survival         | 229305_at  | 236    | 0.01304810  | 2.37 [1.20–4.69] |
| GSE3494-GPL97   | Disease Specific Survival         | 229304_s_at| 236    | 0.00399709  | 4.41 [1.61–12.10]|
| GSE4922-GPL96   | Disease Free Survival             | 218883_s_at| 249    | 0.0051062  | 1.98 [1.35–2.90] |
| GSE4922-GPL97   | Disease Free Survival             | 229305_at  | 249    | 0.00044163  | 2.67 [1.54–4.63] |
| GSE4922-GPL97   | Disease Free Survival             | 229304_s_at| 249    | 0.00811801  | 2.91 [1.32–6.42] |
| GSE2990         | Relapse Free Survival             | 218883_s_at| 125    | 0.00791330  | 1.49 [1.11–2.01] |
| GSE2990         | Distant Metastasis Free Survival  | 218883_s_at| 54     | 0.02650860  | 1.91 [1.08–3.38] |
| GSE2990         | Relapse Free Survival             | 218883_s_at| 62     | 0.01579130  | 1.74 [1.11–2.73] |
| GSE7390         | Relapse Free Survival             | 218883_s_at| 198    | 0.02837110  | 1.30 [1.03–1.65] |
| GSE7390         | Distant Metastasis Free Survival  | 218883_s_at| 198    | 0.00208122  | 1.58 [1.18–2.11] |
| GSE7390         | Overall Survival                  | 218883_s_at| 198    | 0.00025020  | 1.80 [1.31–2.46] |
lncRNAs that can potentially bind with the four above-mentioned key miRNAs. Five such lncRNAs were eventually identified (Table 7). Based on the aforementioned ceRNA theory, two lncRNAs with correlation coefficient absolute values above 0.1 (GATA3-AS1 and PAXIP1-AS1) were selected for subsequent analyses. Furthermore, by using the GEPIA and starBase databases, we found that only GATA3-AS1 exhibited significantly higher levels in malignant samples than in their normal counterparts (Figure 8A–8B). Therefore, we next tried to explore the correlation between GATA3-AS1 expression and survival of breast cancer patients. Our results indicate that higher expression levels of GATA3-AS1 correlate with worse prognosis (Figure 8C). To further verify this finding in vitro, we carried out loss-of-function analyses in breast carcinoma cell lines. Quantitative reverse-transcription PCR (qRT-PCR) assays demonstrated that both GATA3-AS1 and CENPU were markedly overexpressed in MDA-MB-468, BT-549, HCC1954, and MCF-7 (three breast cancer cell lines) than in MCF-10A cells (normal human breast epithelial cells), while the expression of miR-495-3p was lower in breast cancer cell lines than in normal breast epithelial cells (Figure 8D–8F). By silencing GATA3-AS1, CENPU was downregulated (Figure 8G) and miR-495 was

Figure 4. Identification and functional analysis of genes that exhibited co-expression with CENPU. (A) The Venn diagram of CENPU’s co-expressed genes from UALCAN, GEPIA, and cBioPortal databases. (B–D) GO functional annotation (biological process, cellular component, and molecular function) for 180 co-expressed genes of CENPU. (E–G) Pathway (NCI-Nature, Reactome, and KEGG) enrichment analysis for these 180 co-expressed genes of CENPU.
Table 4. The correlation between PLK1 signaling-related genes and CENPU from cBioPortal, GEPIA and UALCAN databases.

| Gene name | R (cBioPortal) | R (GEPIA) | R (UALCAN) |
|-----------|----------------|-----------|------------|
| AURKA     | 0.66           | 0.51      | 0.51       |
| BUB1      | 0.66           | 0.51      | 0.53       |
| BUB1B     | 0.68           | 0.62      | 0.62       |
| CCNB1     | 0.68           | 0.55      | 0.56       |
| CDC20     | 0.57           | 0.32      | 0.34       |
| CDC25C    | 0.67           | 0.62      | 0.61       |
| CDK1      | 0.69           | 0.51      | 0.51       |
| CENPE     | 0.68           | 0.63      | 0.63       |
| ECT2      | 0.54           | 0.56      | 0.56       |
| ERCC6L    | 0.63           | 0.53      | 0.53       |
| FBXO5     | 0.53           | 0.49      | 0.49       |
| KIF20A    | 0.64           | 0.54      | 0.54       |
| NDC80     | 0.65           | 0.49      | 0.49       |
| PLK1      | 0.61           | 0.48      | 0.47       |
| PRC1      | 0.68           | 0.54      | 0.56       |
| TPX2      | 0.68           | 0.54      | 0.54       |
| CLSPN     | 0.55           | 0.53      | 0.53       |

upregulated (Figure 8H) in MCF-7 cells. Additionally, the proliferation of MCF-7 cells was suppressed (Figure 8I). Therefore, GATA3-AS1 was defined as a key lncRNA. Combined with the results obtained from the expression analysis, survival analysis, and correlation analyses, these functional experiments demonstrate a link between the lncRNA GATA3-AS1/miR-495-3p/CENPU axis and the prognosis of breast cancer patients (Figure 8J).

**DISCUSSION**

Despite great efforts have been invested in breast cancer biology during the past decades, the disease still poses a serious threat to the global public health. ER/PR/HER2-negative breast cancer, also defined as triple-negative breast cancer (TNBC), is a most common and life-threatening breast cancer subtype with the worst prognosis [17]. However, the molecular mechanisms underlying TNBC tumorigenesis are still elusive. Therefore, we tried to find a new molecular target for breast cancer treatment in this study. We first analyzed CENPU gene mutations in breast carcinoma patients and found a relatively low incidence of CENPU gene mutation, implying that CENPU gene mutation might not be the key reason for the differences in its mRNA level. Then we analyzed the expression profile of CENPU gene based on the HPA database. Our data indicated that the expression of CENPU was significantly higher in malignant tissues than in normal tissues. Also, CENPU expression significantly correlated with clinical and pathological features of breast carcinoma patients, especially patients with TNBC, implying that the expression of CENPU was closely linked to progression of breast carcinoma. Next, based on the PrognoScan database, we explored the prognostic significance of CENPU expression in breast carcinoma and found that higher CENPU expression levels were predictive of a poorer prognosis. Taken together, these data imply that CENPU is a molecular indicator for breast carcinoma, especially for TNBC.

Next, we explored the mechanism underlying CENPU’s prognostic value in breast cancer. Co-expression analysis identified 180 genes co-expressed with CENPU. Functional annotation demonstrated that these genes were significantly enriched in the PLK1 signaling pathway. Among these genes, 17 were directly involved in the PLK1 signaling pathway. We then observed that most PLK1 signaling pathway-related genes were aberrantly upregulated in breast cancer, and that high expression of most of these genes closely correlated with a poor prognosis. Combined with our previous findings, we propose that CENPU is involved in the PLK1 signaling pathway.

Subsequently, we aimed to explore how CENPU was regulated in breast cancer. It was previously reported that miRNAs are natural inhibitors of oncogenes and suppressors of tumorigenesis [18]. In this study, we identified four miRNAs, namely hsa-miR-543, hsa-miR-495-3p hsa-miR-485-3p, and hsa-miR-337-3p, as key miRNAs that can potentially regulate CENPU expression. Our subsequent lncRNA analysis identified GATA3-AS1, which can bind with has-miR-495-3p, as a key lncRNA. Finally, correlation analysis revealed that only the lncRNA GATA3-AS1/miR-495-3p/CENPU axis conformed to the ceRNA theory. Functional analyses were then carried out to investigate the molecular events downstream of GATA3-AS1 and the relationships between CENPU, miRNA-495, and GATA3-AS1. The RT-qPCR results revealed that GATA3-AS1 exhibited significantly higher expression levels in breast cancer cell lines than in normal control.
In addition, the expression of GATA3-AS1 was positively correlated with CENPU expression and negatively correlated with that of miRNA-495, which is consistent with our bioinformatics analysis results. Finally, in terms of biological function, GATA3-AS1 knockdown inhibited the proliferation of breast cancer cells. These results suggest that GATA3-AS1 plays a crucial role in tumorigenesis of breast cancer.

In conclusion, using integrated bioinformatics analysis, we found a novel IncRNA-miRNA-mRNA axis of high prognostic value in breast carcinoma. More experiments

Figure 5. (A–Q) Prognostic value of the 17 genes that exhibited co-expression with CENPU and are involved in the PLK1 pathway in breast cancer. **P < 0.01.
and large-scale clinical trials are required in the future to further verify our results.

**MATERIALS AND METHODS**

**Analysis based on the COSMIC database**

COSMIC is an online database containing information about all types of genomic alteration in human malignancies [19]. Using COSMIC version 91, we summarized gene mutations that can potentially affect CENPU expression. All the data were retrieved on April 7, 2020.

**Analysis based on the HPA database**

The HPA database is dedicated to providing immunohistochemical data regarding the expression and distribution of 24,000 identified human proteins in multiple types of cells, cell lines and normal or cancerous tissues [20]. Based on this database, we determined CENPU expression in various normal and cancerous tissues.

**Correlations between CENPU levels and clinical and pathohistological characteristics in breast carcinoma**

Differences in CENPU expression in breast carcinoma patients with diverse clinical and pathological parameters were investigated based on bc-GenExMiner [21], a database exhibiting gene expression profiles in breast cancer patients. CENPU expression was examined in patients with different ages, SBR grades, Nottingham prognostic index (NPI) scores, lymph node statuses, ER statuses, PR statuses, HER2 statuses, HU’s

![Figure 6](image)

Figure 6. Gene set enrichment analyses were performed using gene expression data of 226 African-American women with triple negative breast cancer (TNBC). (A) Genes are enriched in PLK1 pathway. (B) Genes are enriched in Fisher G2-M cell cycle. (C) Genes are enriched in the Reactome cell cycle mitotic. (D) Genes are enriched in Reactome cell cycle. False discovery rate (FDR) q value, normalized enrichment score (NES), and P values are shown, vs: versus.
Table 5. The correlation between predicted miRNA and CENPU.

| Predicted miRNA | R   | P-value  |
|-----------------|-----|----------|
| hsa-miR-543     | -0.109 | 3.30e-4  |
| hsa-miR-495-3p  | -0.107 | 4.30e-4  |
| hsa-miR-493-3p  | -0.070 | 2.18e-2  |
| hsa-miR-656-3p  | -0.164 | 5.91e-8  |
| hsa-miR-1295a   | -0.062 | 4.23e-2  |
| hsa-miR-485-3p  | -0.105 | 5.03e-4  |
| hsa-miR-337-3p  | -0.173 | 9.41e-9  |
| hsa-miR-411-5p  | -0.149 | 7.79e-7  |

Table 6. The expression of potential miRNAs in breast cancer from OncomiR database.

| miRNA Name     | T-test P-value | T-test FDR | Downregulated | Tumor log2 mean expression | Normal log2 mean expression |
|----------------|----------------|------------|---------------|---------------------------|-----------------------------|
| hsa-miR-543    | 5.77e-06       | 1.77e-05   | Tumor         | 0.10                      | 0.47                        |
| hsa-miR-495-3p | 5.49e-20       | 6.89e-19   | Tumor         | 2.43                      | 3.98                        |
| hsa-miR-656-3p | 4.58e-08       | 1.69e-07   | Tumor         | 0.09                      | 0.51                        |
| hsa-miR-1295a  | 5.05e-10       | 2.33e-09   | Tumor         | 0.35                      | 1.12                        |
| hsa-miR-485-3p | 3.78e-07       | 1.31e-06   | Tumor         | 1.83                      | 2.57                        |
| hsa-miR-337-3p | 4.52e-24       | 1.02e-22   | Tumor         | 5.08                      | 6.82                        |
| hsa-miR-411-5p | 4.81e-16       | 3.88e-15   | Tumor         | 1.96                      | 3.14                        |

subtypes, RSSPC subtypes, basal-like statuses, and triple-negative statuses.

Analysis based on the Oncomine database

Oncomine is an online discovery platform providing transcriptomic information based on 715 datasets obtained from 86,733 cancerous and normal tissue samples [22]. Using Oncomine version 4.5, gene expression profiles were analyzed and compared between different types and subtypes of malignancy, among cancer patients with different clinicopathological features, and between cancerous and normal tissues.

Analyses based on the Kaplan–Meier plotter and progoScan databases

Kaplan-Meier plotter is a database that provides information about the correlation between expression of a specific gene and survival of cancer patients [23].

Figure 7. (A–G) Prognostic significance of the seven miRNAs that can potentially regulate CENPU expression in breast cancer analyzed by Kaplan-Meier plotter database.
Table 7. The correlation between miRNA-lncRNA pairs in breast cancer identified by starBase database.

| miRNA       | lncRNA   | R       | P-value |
|-------------|----------|---------|---------|
| has-miR-543 | NORAD    | -0.082  | 6.65e-3 |
| has-miR-495-3p | NORAD    | -0.060  | 4.66e-2 |
|             | JPX      | -0.098  | 1.28e-3 |
|             | PURPL    | -0.061  | 4.35e-2 |
|             | GATA3-AS1| -0.126  | 3.26e-5 |
|             | PAXIP1-AS1| -0.178  | 3.73e-9 |
| hsa-miR-485-3p |          |         |         |

PrognoScan is a newly established base that collects meta-analyses of prognostic significance of different genes in various human malignancies [24]. We previously explored the expression of CENPU in cancerous and normal tissues of breast carcinoma patients based on the online database UALCAN [25]. In this research, we investigated the correlations between CENPU expression and OS, RFS, DMFS, or post-

Figure 8. Expression and biological significance of the lncRNA GATA3-AS1 in breast carcinoma. (A) Expression levels of GATA3-AS1 in breast carcinoma as determined with GEPIA. (B) Expression levels of GATA3-AS1 in breast cancer as determined with the starBase database. (C) Prognostic value of GATA3-AS1 in breast cancer as determined with GEPIA. (D–F) Relative expression levels of GATA3-AS1, CENPU, and miR-495-3p in MDA-MB-468, BT-549, HCC1954, MCF-7, and MCF-10A cell lines as determined by qRT-PCR. (G) Western blotting analysis of CENPU protein levels in MCF-7 cells after the cells were transfected with sh-NC, sh-GATA3-AS1#1, sh-GATA3-AS1#2. (H) Quantitative RT-PCR analysis of miR-495-3p levels in MCF-7 cells after the cells were transfected with sh-NC, sh-GATA3-AS1#1, sh-GATA3-AS1#2. (I) Proliferation of MCF-7 cells after the cells were transfected with sh-NC, sh-GATA3-AS1#1, sh-GATA3-AS1#2 by MTT assay. (J) The identified lncRNA-miRNA-mRNA axis that can predict the prognosis of breast cancer patients. **P < 0.01, *P < 0.05.
progression survival in those patients by utilizing the Kaplan-Meier plotter database. In addition, genes exhibited co-expression with CENPU were identified based on the UALCAN database, and their prognostic values were predicted based on the Kaplan-Meier plotter database.

Analyses of genes co-expressed with CENPU

We characterized genes that exhibited co-expression with CENPU using the cBioPortal [26], GEPIA [27], and UALCAN databases. To characterize the functions of these genes, GO annotation and pathway enrichment analyses were carried out based on the Enrichr database [28].

To obtain a better understanding of the functions of these genes, we retrieved raw microarray data from the gene expression omnibus (GEO) database. The dataset GSE142102 obtained based on platform GPL17692 from a cohort of 226 African-American female TNBC patients was used. Subsequently, these 226 samples were categorized into two groups depending on the level of CENPU expression (high vs. low). GSEA [29] was then carried out utilizing the optimal cut-off expression values established for event-free survival (EFS). We enriched gene sets obtained from the MSigDB “Curated” gene set collection (https://www.gsea-msigdb.org/gsea/msigdb/genesets.jsp) in both the CENPU-high and the CENPU-low groups.

Analysis of key miRNAs and lncRNAs

We predicted miRNAs and lncRNAs that can potentially regulate CENPU expression by using starBase, a comprehensive online resource for prediction of microRNAs and IncRNAs [30]. Then we validated the functions and prognostic values of the predicted genes by using Gene Expression Profiling Interactive Analysis (GEPIA) (http://geopia.cancer-pku.cn/detail.php), a novel online server for analysis of RNA-seq data deposited in TCGA and GTEx.

Cell viability assay

Equal amounts (2 × 10^3) of cells were seeded into each well of five 96-well plates. The cells were cultured for five consecutive days and added with 20 μL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, final concentration 5 mg/mL). Afterwards, the cells were maintained at 37°C, 5% CO₂ for another 4 hours, and the MTT solution was removed. The 490-nm optical absorption value of each well was obtained and cell growth curves were established accordingly by using the Graphpad Prism 5.0 software.

Quantitative reverse transcription PCR (qRT-PCR)

Total RNA was extracted from cells using the TRIzol reagent (Invitrogen) as per the manufacturer’s protocol. The RNA was then reverse-transcribed into cDNA using a cDNA synthesis kit (Promega). After that, relative expression levels of target genes were quantified by qRT-PCR assays with the SYBR Premix Ex Taq II kit (Toyobo) on an Applied Biosystems 7500 Real-Time PCR platform (Applied Biosystems). The following primers were used in this experiment: GATA3-AS1 F: 5′-TTGTTCCCTCTTCGCTCCT-3′ and GATA3-AS1 R: 5′-TTGTTCCCTCACCGCATG-3′; CENPU F: 5′-ATGAAACTGCTTCGGTTAGAGC-3′ and CENPU R: 5′-ATTTCGAGATGGCTTTCC-3′; and miR-495 F: 5′-ACACTCCAGCTGGGAAGTTGCCCATGTT-3′ and miR-495 R: 5′-CTCAACTGGTGTCGGAGG-3′; The 2-ΔΔCt method was utilized for calculation of relative fold changes of target genes, with the expression level of GAPDH gene as the internal reference.

Immunoblotting

MCF-7 cell lysates were prepared and electrophoresed on 10% sodium dodecyl sulfate polyacrylamide gel for separation of proteins, which were then electro-blotted onto polyvinyl fluoride membranes (Millipore). After being incubated in 5% non-fat dry milk [dissolved in Tris-buffered saline Tween (TBST)] for 1 h at ambient temperature, the membranes were probed with primary antibodies raised against our target proteins at 4°C overnight. After being rinsed with TBST for three times, the membranes were subjected to incubation in horseradish peroxidase (HRP)-conjugated secondary antibodies for 1 h at ambient temperature. The protein bands were eventually developed by using the Enhanced Chemiluminescence Western Blotting Substrate kit (Pierce). The primary antibodies used in this study included rabbit anti-CENPU (diluted 500-fold; Abcam, ab117078) and mouse anti-GAPDH (diluted 2000-fold;
Santa Cruz, CA 95060; the secondary antibodies used in this study included goat anti-rabbit IgG (diluted 2000-fold; Santa Cruz, sc-2004) and goat anti-mouse IgG (diluted 2000-fold; Santa Cruz, sc-2005).

Statistical analysis

At least three replicates were carried out for each experiment, and the results were analyzed by the GraphPad prism 5.0 software (GraphPad Software, Inc.). Quantitative data are displayed as mean ± S.D. We performed Student’s t-test to evaluate the statistical significance of intergroup differences, and a P value < 0.05 was regarded as statistically significant.

AUTHOR CONTRIBUTIONS

Shiping Ding and Fang Peng contributed significantly to the design and conception of the study. Yanbo Lv, Genxiang Mao, Shuangyan Lin and Mingyuan Zhao all participated in data acquisition. Shuangyan Lin and Mingyuan Zhao also analyzed and interpreted the data. Shuangyan Lin wrote the manuscript; Shiping Ding and Fang Peng revised the manuscript carefully and provided valuable advices.

CONFLICTS OF INTEREST

The authors have no conflicts of interest to declare.

FUNDING

The research was supported by the key disciplines of Zhejiang Hospital, the Zhejiang Provincial Public Welfare Technology Research Program (LGF18H160028, LGF19260013), National Natural Science Foundation (81771520), and Zhejiang Provincial Health Bureau Foundation (2019KY257).

Editorial Note

This corresponding author has a verified history of publications using the personal email address for correspondence.

REFERENCES

1. Corey B, Smania MA, Spotts H, Andersen M. Young Women With Breast Cancer: Treatment, Care, and Nursing Implications. Clin J Oncol Nurs. 2020; 24:139–47. https://doi.org/10.1188/02.CJON.139-147 PMID:32196004

2. Mustillo A, Ayoub JP, Charpentier D, Yelle L, Florescu M. Prognosis in young women less than 40 years of age with brain metastasis from breast cancer. Curr Oncol. 2020; 27:39–45. https://doi.org/10.3747/co.27.5621 PMID:32218659

3. Fabiano V, Mandop P, Rizzo M, Ponce C, Coló F, Loza M, Loza J, Amat M, Mysler D, Costanzo MV, Nervo A, Nadal J, Perazzo F, Chacón R, and RCM Database Contributors. Breast Cancer in Young Women Presents With More Aggressive Pathologic Characteristics: Retrospective Analysis From an Argentine National Database. JCO Glob Oncol. 2020; 6:639–46. https://doi.org/10.1200/JGO.19.00228 PMID:32315233

4. Anastasiadi Z, Lianos GD, Ignatiadou E, Harissis HV, Mitsis M. Breast cancer in young women: an overview. Updates Surg. 2017; 69:313–17. https://doi.org/10.1007/s13304-017-0424-1 PMID:28260181

5. Hanissian SH, Akbar U, Teng B, Janjetovic Z, Hoffmann A, Hitzler JK, Iscove N, Hamre K, Du X, Tong Y, Robertson JH, Morris SW. cDNA cloning and characterization of a novel gene encoding the MLF1-interacting protein MLF1IP. Oncogene. 2004; 23:3700–07. https://doi.org/10.1038/sj.onc.1207448 PMID:15116101

6. Kang YH, Park JE, Yu LR, Soung NK, Yun SM, Bang JK, Seong YS, Yu H, Garfield S, Veenstra TD, Lee KS. Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBP1 interaction is critical for proper chromosome segregation. Mol Cell. 2006; 24:409–22. https://doi.org/10.1016/j.molcel.2006.10.016 PMID:17081991

7. Hua S, Wang Z, Jiang K, Huang Y, Ward T, Zhao L, Dou Z, Yao X. CENP-U cooperates with Hec1 to orchestrate kinetochore-microtubule attachment. J Biol Chem. 2011; 286:1627–38. https://doi.org/10.1074/jbc.M110.174946 PMID:21056971

8. Lin SY, Lv YB, Mao GX, Chen XJ, Peng F. The effect of centromere protein U silencing by lentiviral mediated RNA interference on the proliferation and apoptosis of breast cancer. Oncol Lett. 2018; 16:6721–28. https://doi.org/10.3892/ol.2018.9477 PMID:30405814

9. Bertoli G, Cava C, Castiglioni I. MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer. Theranostics. 2015; 5:1122–43. https://doi.org/10.7150/thno.11543 PMID:26199650
10. Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016; 17:47–62. https://doi.org/10.1038/nrg.2015.10 PMID:26666209

11. Maqbool R, Ul Hussain M. MicroRNAs and human diseases: diagnostic and therapeutic potential. Cell Tissue Res. 2014; 358:1–15. https://doi.org/10.1007/s00441-013-1787-3 PMID:24493638

12. Atkinson SR, Marguerat S, Bähler J. Exploring long non-coding RNAs through sequencing. Semin Cell Dev Biol. 2012; 23:200–05. https://doi.org/10.1016/j.semcdb.2011.12.003 PMID:22202731

13. Moran VA, Perera RJ, Khalil AM. Emerging functional and mechanistic paradigms of mammalian long non-coding RNAs. Nucleic Acids Res. 2012; 40:6391–400. https://doi.org/10.1093/nar/gks296 PMID:22492512

14. Perez-Balaguer A, Ortiz-Martínez F, García-Martínez A, Pomares-Navarro C, Lerma E, Peiró G. FOXA2 mRNA expression is associated with relapse in patients with Triple-Negative/Basal-like breast carcinoma. Breast Cancer Res Treat. 2015; 153:465–74. https://doi.org/10.1007/s10549-015-3553-6 PMID:26298189

15. Lou W, Liu J, Ding B, Xu L, Fan W. Identification of chemoresistance-associated miRNAs in breast cancer. Cancer Manag Res. 2018; 10:4747–57. https://doi.org/10.2147/CMAR.S172722 PMID:30425571

16. Song J, Ye A, Jiang E, Yin X, Chen Z, Bai G, Zhou Y, Liu J. Reconstruction and analysis of the aberrant lncRNA-miRNA-mRNA network based on competitive endogenous RNA in CESC. J Cell Biochem. 2018; 119:6665–73. https://doi.org/10.1002/jcb.26850 PMID:29741786

17. Bao B, Prasad AS. Targeting CSC in a Most Aggressive Subtype of Breast Cancer TNBC. Adv Exp Med Biol. 2019; 1152:311–34. https://doi.org/10.1007/978-3-030-20301-6_17 PMID:31456192

18. Le XF, Merchant O, Bast RC, Calin GA. The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade. Cancer Microenviron. 2010; 3:137–47. https://doi.org/10.1007/s12307-010-0037-4 PMID:21209780

19. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, Flanagan A, Teague J, Futreal PA, Stratton MR, Wooster R. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 2004; 91:355–58. https://doi.org/10.1038/sj.bjc.6601894 PMID:15188009

20. Pontén F, Schwenk JM, Asplund A, Edqvist PH. The Human Protein Atlas as a proteomic resource for biomarker discovery. J Intern Med. 2011; 270:428–46. https://doi.org/10.1111/j.1365-2796.2011.02427.x PMID:21752111

21. Jézéquel P, Campone M, Gouraud W, Guérin-Charbonnel C, Leux C, Ricolleau G, Campion L. bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res Treat. 2012; 131:765–75. https://doi.org/10.1007/s10549-011-1457-7 PMID:21452023

22. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaian AM. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004; 6:1–6. https://doi.org/10.1016/s1476-6072(04)80047-2 PMID:15068665

23. Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010; 123:725–31. https://doi.org/10.1007/s10549-009-0674-9 PMID:20020197

24. Mizuno H, Kitada K, Nakai K, Sarai A. PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics. 2009; 2:18. https://doi.org/10.1186/1755-8794-2-18 PMID:19393097

25. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BV, Varambally S. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017; 19:649–58. https://doi.org/10.1016/j.neo.2017.05.002 PMID:28732212

26. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2:401–04. https://doi.org/10.1158/2159-8290.CD-12-0095 PMID:22588877
27. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45:W98–W102. 
https://doi.org/10.1093/nar/gkx247
PMID:28407145

28. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, Koplev S, Jenkins SL, Jagodnik KM, Lachmann A, McDermott MG, Monteiro CD, Gundersen GW, Ma'ayan A. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016; 44:W90–97. 
https://doi.org/10.1093/nar/gkw377
PMID:27141961

29. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102:15545–50. 
https://doi.org/10.1073/pnas.0506580102
PMID:16199517

30. Yang JH, Li JH, Shao P, Zhou H, Chen YQ, Qu LH. starBase: a database for exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data. Nucleic Acids Res. 2011; 39:D202–09. 
https://doi.org/10.1093/nar/gkq1056
PMID:21037263
SUPPLEMENTARY MATERIALS

Supplementary Table

Supplementary Table 1. GSEA details of PLK1 pathway enriched genes in TNBC patients with CENPU high vs. CENPU low.

| Gene Name | Rank Metric Score | Running ES | Core Enrichment |
|-----------|-------------------|------------|-----------------|
| PLK1      | 1.673963785       | 0.14937250 | Yes             |
| TPX2      | 0.954416513       | 0.23453778 | Yes             |
| CDC20     | 0.941986740       | 0.31859392 | Yes             |
| CENPE     | 0.829827487       | 0.39264175 | Yes             |
| NDC80     | 0.765826583       | 0.45612425 | Yes             |
| CCNB1     | 0.685156107       | 0.51726264 | Yes             |
| BUB1      | 0.649955809       | 0.5655130  | Yes             |
| KIF20A    | 0.647423625       | 0.62332270 | Yes             |
| ECT2      | 0.623647332       | 0.66926384 | Yes             |
| CENPU     | 0.608254910       | 0.71868575 | Yes             |
| CDK1      | 0.524208784       | 0.76060800 | Yes             |
| PRC1      | 0.456795961       | 0.79651480 | Yes             |
| BUB1B     | 0.417752266       | 0.81922895 | Yes             |
| ERCC6L    | 0.369548827       | 0.84735040 | Yes             |
| FBXO5     | 0.342099875       | 0.86331385 | Yes             |
| AURKA     | 0.262047052       | 0.86242520 | No              |
| CLSPN     | 0.129781887       | 0.79633610 | No              |
| CDC25C    | -0.323945820      | 0.04854368 | No              |